Leslie Servidio

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection

Ross A. Soo, Filippo de Marinis, Ji‐Youn Han et al. · Clinical Lung Cancer · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib

Nir Peled, Amanda Tufman, Lecia V. Sequist et al. · ESMO Open · 2025 · 17 citations · Full text

Medicine, Oncology, Pharmacology +14

P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib

Lecia V. Sequist, Nir Peled, Amanda Tufman et al. · Journal of Thoracic Oncology · 2021 · 16 citations · Full text

Medicine, Oncology, Pharmacology +9

Characteristics and overall survival of patients with early‐stage non‐small cell lung cancer: A cohort study in Denmark

Véra Ehrenstein, Katrine Eriksen, Aliki Taylor et al. · Cancer Medicine · 2022 · 15 citations · Full text

Medicine, Biostatistics, Oncology +15

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data

Parneet Cheema, Byoung Chul Cho, H. Freitas et al. · Future Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacology +16